Remedy Plan
Gaithersburg, MD · Biotechnology, Healthcare · 9 employees
Remedy Plan Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel, hyperbolic NAMPT inhibitors. NAMPT is an enzyme that controls how cells use energy and is core to human biology. It is dysregulated in more than 20 diseases spanning oncology, autoimmunity, and metabolic disorders. Previous efforts by others to inhibit NAMPT activity resulted in severe on-target t
Funding history
- Funding Round — $18.0M — May 2025
- Funding Round — $19.1M — Aug 2023
- Funding Round — $5.2M — Dec 2019
- Series seed — $1.5M — Nov 2018
Recent signals
- May 13, 2025: Raised $18.0M
- Aug 10, 2023: Raised $19.1M
- Dec 02, 2019: Raised $5.2M
- Nov 20, 2018: Raised $1.5M in Series seed
See plans & pricing → Track Remedy Plan’s funding, hiring, and signals — with verified contacts — on Fundz.